| Metric | Oct 18, 2024 FY24 Q3 | Jan 31, 2025 FY24 Q4 | Apr 16, 2025 FY25 Q1 | Jul 18, 2025 FY25 Q2 | Oct 17, 2025 FY25 Q3 | Jan 30, 2026 FY25 Q4 | Apr 17, 2026 FY26 Q1 | Jul 17, 2026 FY26 Q2 |
|---|---|---|---|---|---|---|---|---|
| For FY2029 | ||||||||
| Share repurchase program | — | — | — | New“up to $2.5 billion” | — | — | — | — |
| For FY2028 | ||||||||
| Türkiye manufacturing operations complete closure | — | — | — | — | — | — | — | New“anticipated in the first half of 2028” |
| For FY2027 | ||||||||
| Türkiye restructuring annual pre-tax savings | — | — | — | — | — | — | — | New“$40 million” |
| For FY2026 | ||||||||
| FX effect on net sales | — | — | — | — | — | New“Around 1% positive” | — | — |
| FX impact on net sales | — | — | — | — | — | — | New“Around 3% positive” | Lowered“Around 2.5% positive” |
| Adjusted operating margin | — | — | — | — | — | New“Around 10.5-11.0%” | Reiterated“Around 10.5-11%” | Reiterated“Around 10.5-11%” |
| Adjusted operating margin | — | — | — | — | — | — | — | New“around the first half 2026 level” |
| Adjusted operating margin | — | — | — | — | — | New“considerably weaker than Q1 2025, with improvements in the following three quarters” | — | — |
| Tariff-related dilution on operating margin | — | — | — | — | — | — | New“similar to the around 20 bps that it was for full year 2025” | Reiterated“similar to the around 20 bps for full year 2025” |
| Call-off volatility | — | — | — | — | — | — | New“slightly improved compared to 2025” | — |
| Capex, net, % of sales | — | — | — | — | — | New“Less than 5%” | Reiterated“Less than 5%” | Reiterated“Less than 5%” |
| Gross impact from higher raw material prices | — | — | — | — | — | — | New“around $90 million” | Raised“around $110 million” |
| LVP decline assumption | — | — | — | — | — | — | — | New“around 2.5%” |
| LVP growth | — | — | — | — | — | New“Around 1% negative” | Reiterated“Around 1% negative” | Raised“Around 2.5% negative” |
| Operating cash flow | — | — | — | — | — | New“Around $1.2 billion” | Reiterated“Around $1.2 billion” | Reiterated“Around $1.2 billion” |
| Organic sales growth | — | — | — | — | — | New“Around 0%” | Reiterated“Around 0%” | Reiterated“Around 0%” |
| Repurchase shares | — | — | — | — | — | — | New“$300-500 million” | — |
| Sales growth in China | — | — | — | — | — | New“continued strong” | — | — |
| Sales performance with COEMs | — | — | — | — | — | New“continued strong” | — | — |
| Share repurchases | — | — | — | — | — | — | — | New“$300-500 million” |
| Tax rate | — | — | — | — | — | New“Around 28%” | Reiterated“Around 28%” | Raised“Around 30%” |
| For FY2025 | ||||||||
| FX effect on net sales | — | New“Around 2% negative” | Raised“Around 3% negative” | Lowered“Around 0%” | Raised“Around 1%” | — | — | — |
| Adjusted operating margin | — | New“Around 10-10.5%” | Reiterated“Around 10-10.5%” | Reiterated“around 10-10.5%” | Reiterated“Around 10-10.5%” | — | — | — |
| Tariff dilution on operating margin | — | — | — | New“around 20 bps” | — | — | — | — |
| Tariff dilution on our operating margin | — | — | — | — | New“around 20 bps” | — | — | — |
| Autoliv 2029 stock repurchase program | — | — | — | — | — | — | — | New“$2.5 billion” |
| Capex, net, % of sales | — | New“Around 5%” | Reiterated“Around 5%” | Reiterated“Around 5%” | Lowered“Around 4.5%” | — | — | — |
| Dividend increase | — | — | — | New“21%” | — | — | — | — |
| Dividend per share | — | — | — | New“$0.85 per share” | — | — | — | — |
| LVP growth | — | New“Around 0.5% negative” | Reiterated“Around 0.5% negative” | Reiterated“Around 0.5% negative” | Raised“Around 1.5%” | — | — | — |
| Operating cash flow | — | New“Around $1.2 billion” | Reiterated“Around $1.2 billion” | Reiterated“Around $1.2 billion” | Reiterated“Around $1.2 billion” | — | — | — |
| Organic sales growth | — | New“Around 2%” | Reiterated“Around 2%” | Raised“around 3%” | Reiterated“Around 3%” | — | — | — |
| Raw material costs | — | — | — | New“slightly higher than in 2024” | — | — | — | — |
| Share repurchase program | — | New“extension of its share repurchase program until the end of 2025, with no other changes to the authorization” | — | — | — | — | — | — |
| Tax rate | — | New“Around 28%” | Reiterated“Around 28%” | Reiterated“Around 28%” | Reiterated“Around 28%” | — | — | — |
| For FY2024 | ||||||||
| FX effect on net sales | New“Around 1% negative” | — | — | — | — | — | — | — |
| Adjusted operating margin | New“Around 9.5-10.0%” | — | — | — | — | — | — | — |
| Capex, net, of sales | New“Around 5.5%” | — | — | — | — | — | — | — |
| Operating cash flow | New“Around $1.1 billion” | — | — | — | — | — | — | — |
| Organic growth | New“1%” | — | — | — | — | — | — | — |
| Organic sales growth | New“Around 1%” | — | — | — | — | — | — | — |
| Tax rate | New“Around 28%” | — | — | — | — | — | — | — |
| No period stated | ||||||||
| Adjusted operating margin target | — | — | — | — | — | New“12%” | — | — |
| Cash outflow | — | — | — | — | — | — | — | New“approximately $129 million” |
| Complete closure | — | — | — | — | — | — | — | New“anticipated in the first half of 2028” |
| Leverage ratio | — | New“around 1.0x within a range of 0.5x to 1.5x” | — | — | — | — | — | — |
| Leverage ratio (long-term target) | New“around 1.0x within a range of 0.5x to 1.5x” | — | Reiterated“around 1.0x within a range of 0.5x to 1.5x” | Changed“equal to or below 1.5x” | — | — | — | — |
| Leverage ratio target | — | — | — | — | — | New“equal to or below 1.5x” | Reiterated“equal to or below 1.5x” | Raised“not higher than 1.5x” |
| Restructuring charges | — | — | — | — | — | — | — | New“approximately $142 million in total” |
| Share repurchase program | — | — | — | New“new share repurchase program of up to $2.5 billion until the end of 2029” | — | — | — | — |
| Türkiye restructuring cash outflow | — | — | — | — | — | — | — | New“approximately $129 million” |
| Türkiye restructuring charges, total | — | — | — | — | — | — | — | New“approximately $142 million” |